A study on mefloquine-associated neuropsychiatric manifestations among Nepalese soldiers posted for United Nations peace mission

Katuwal N1, Khatri D2, Shrestha DB3, Dhungel O4, Oli PR5, Aryal BB5, Rawal N1, Rana KJB2, Manandhar P1, Panta C2

1Nagendra Katuwal, Lecturer; Namrata Rawal, Associate Professor; Pradeep Manandhar, Lecturer; Department of Neuropsychiatry, Shree Birendra Hospital, Chhauni; Nepalese Army Institute of Health Sciences (NAIHS). 2Devendra Khatri, Associate Professor; Kishor JB Rana, Professor; Chiranjibi Panta, Lecturer; Department of Medicine, Shree Birendra Hospital, Chhauni; NAIHS. 3Dhan Bahadur Shrestha, Medical Officer; Mangalbare Hospital, Urlabari, Morang, Nepal. 4 Omkar Dhungel, Medical Officer; Shree Birendra Hospital, Chhauni. 5Prakash Raj Oli & Barun Babu Aryal, Intern; Shree Birendra Hospital, Chhauni.

Abstract

Background: Mefloquine is one of the prophylactic medications recommended by the government of Nepal. In areas of intense malaria transmission, prophylaxis with drugs is an important strategy to prevent malaria. During prophylactic use, several neuro-psychiatric and other systemic adverse effects can occur with mefloquine. Notable psychiatric manifestations include anxiety, depression, restlessness, and confusion.

Objective: To study the psychiatric effects of mefloquine in Nepalese serving soldiers posted in the United Nations peace mission nations of the African continent taking mefloquine prophylaxis.

Methodology: This prospective descriptive study was conducted among Nepalese soldiers posted for United Nations peace mission in South Sudan over a period of one year. Soldiers of age group 25-55 years posted for peace mission having no past and family history of psychiatric illnesses were enrolled in the study. General Health Questionnaire-12, translated into Nepali by Nepalese Journal of Psychiatry, with a questionnaire about the side effects was used to collect detailed information.

Results: A total of 524 soldiers posted on peace mission were enrolled in the present study, among which 520 were male and four were female. There were four positive cases with General Health Questionnaire score 3/12 or more. Among the adverse events noted, neuropsychiatric adverse events were more common than non-neuropsychiatric adverse events but none were of life-threatening severity.

Conclusion: In a malaria endemic region with a high prevalence of malaria, mefloquine can be safely used in an apparently healthy population, judging the risk-benefit.

Key words: Mefloquine; Nepal army; Neuro-psychiatric manifestation

INTRODUCTION

The number of soldiers going on United Nations (UN) peacekeeping missions annually is around 10,000 with current deployment 4366, in the different countries allocated by the UN1. Malaria is endemic in 109 countries and these countries are visited by more than 125 million travelers each year. About 10,000 international travelers from non-endemic areas who lack immunity to malaria fall ill with malaria after returning home from travel to malaria-endemic countries2 and the real figure may be up to 30,000 as they were underdiagnosed, treated aboard or underreporting. About 1-4% of travelers who acquire P. falciparum malaria will die. Travelers to sub-Saharan Africa are most at risk of contracting malaria. Recent estimates suggest an attack rate of malaria of 302 in 100,000 travelers to West Africa compared to lower rates in Southern Africa (49/100,000) and much...
lower rates in East Asia (5.4/100,000) and the Americas (1/100,000)\(^3\). In Nepal, there were 1,674 confirmed cases of malaria in 2070/71 B.S, with 585 imported cases. The proportion of \emph{P. falciparum} infections were 13 percent in the reporting year. The total \emph{P. falciparum} cases were 224 and among them, 142 were imported\(^4\). Most cases of imported malaria are preventable using appropriate chemoprophylaxis, but many travelers fail to use or comply with appropriate chemoprophylaxis\(^5\). An important factor contributing to this failure is the concern about side effects associated with antimalarial chemoprophylaxis. Along with atovaquone/proguanil and doxycycline, mefloquine is currently recommended as malaria prophylaxis for travel in areas with chloroquine-resistant \emph{Plasmodium falciparum}\(^6\).

There have been many neuropsychiatric disturbances of mefloquine use reported in the literature since its use in therapy for malaria treatment and prophylaxis. In spite of this, it is in use in several countries as a prophylactic agent these days too\(^6\). During prophylactic use, the occurrence of psychiatric symptoms such as acute anxiety, depression, restlessness or confusion suggests a risk for more serious psychiatric disturbances or neurologic adverse reactions\(^6\). Though there are many reports from the all over the world, the neuropsychiatric manifestations among Nepalese soldiers using mefloquine as a prophylactic medication for malaria are unknown.

In order to investigate these effects, this prospective study was conducted on Nepalese serving soldiers posted in UN peace mission nations of the African continent taking mefloquine prophylaxis to observe the psychiatric effects of mefloquine.

**METHODOLOGY**

The study was conducted among Nepalese soldiers deployed for UN peace mission in South Sudan. This was a descriptive study conducted over a period of one year from 15\(^{th}\) Aug 2015 to 15\(^{th}\) Sept 2016.

\textit{Inclusion criteria:} Nepalese soldiers of age group 25-55 years posted for UN peace mission, confirmed to be taking mefloquine, and having no past and family history of psychiatric illnesses.

\textit{Exclusion criteria:} Soldiers having a past history of neuropsychiatric disorders or a family history of neuropsychiatric disorders, seizure disorder, head injury, excessive alcohol consumption and those below the age of 25 and above the age of 55 years.

General Health Questionnaire-12 (GHQ-12), a validated scale developed to measure mental health\(^7\). Its translated version from English to Nepali by Nepalese Journal of Psychiatry was used in the study to identify a deviation in mental health among serving soldiers under mefloquine prophylaxis. In addition to GHQ, mefloquine side effect questionnaire (developed by Lariam action; an independent information and support group for people with mefloquine toxicity) was used in an interview to collect detailed information about health condition before, during and after the completion of mefloquine prophylactic regimen. These questionnaires were used by medical officer posted on UN mission (co-author of this study) to collect the data. The GHQ was considered positive if it came with score $\geq 3/12$. Among positive cases, further detailed inquiry was made to dig down the problem patient was having, using a side effect questionnaire to get the systemic symptomatology.

During that time period, the subjects were informed about the nature of the study and informed consent was obtained. They were asked about their previous illness, any family history of psychiatric illness, history of seizure or alcohol abuse. Then, they were provided with a questionnaire and asked to tick on the true options regarding their health state. About 50 subjects were dealt on a daily basis and completed in around 10 days. The reassessment was repeated every 4 months with a total of four assessments done by the same medical officer. Two assessments were done in Nepal at Shree Birendra Hospital (before commencing treatment and after completion of the regimen); rest two assessments were done in Sudan.

Any participant having three or more criteria positive in GHQ was identified as positive. The positive cases were followed up closely, keeping their identity a secret by supervising medical officer in Sudan. Among positive cases, mefloquine was stopped and provided with protective measures for a mosquito bite. The follow up (twice a week) and counseling about the side effects of mefloquine helped most of the positive cases, while in one of them tablet diazepam 5 mg was given for sleeplessness and anxiety for 5 days. All cases were followed up four-monthly and their physical and psychological conditions were closely observed. All patients were provided with medication under direct supervision. Being army personnel was the one who gets exposed to long term prophylactic mefloquine therapy and most previous study were a case based this study was carried out.
The institutional ethical review committee of NAISHS granted the ethical clearance to conduct this study. The Nepal army corps, Director General of Medical Services (DGMS) gave the permission to conduct the study. Explained written consent was taken from all the participants voluntarily.

RESULTS
Out of the total 524 soldiers enrolled, 520 were male and rests 4 were females. There were 4 positive cases with a GHQ score ≥3/12. Each positive case reported multiple adverse events. The incidence rate of mefloquine-associated neuropsychiatric manifestations is 7.6 cases per 1,000 study populations. Mean age was 32.26±4.62 years with age ranging from 23-53 years.

Table 1: Mefloquine-associated adverse manifestations

| Adverse events                                      | Number(s) | %  |
|-----------------------------------------------------|-----------|----|
| Neuropsychiatric adverse events                     |           |    |
| Insomnia/sleep disturbances                         | 3         | 0.57 |
| Headache                                            | 3         | 0.57 |
| Memory impairment, confusion                        | 2         | 0.38 |
| Dizziness or vertigo                                | 2         | 0.38 |
| Blurred or double vision                            | 2         | 0.38 |
| Difficulty in concentration                         | 1         | 0.19 |
| Abnormal dreams                                     | 1         | 0.19 |
| Aggression                                          | 1         | 0.19 |
| Psychotic episodes                                  | 1         | 0.19 |
| Mood swings/changes                                 | 1         | 0.19 |
| Loss of coordination                                | 1         | 0.19 |
| Suicidal ideation                                   | 1         | 0.19 |
| Non-neuropsychiatric adverse events                 |           |    |
| Disturbances in heartbeat                          | 2         | 0.38 |
| Fatigue, malaise                                    | 1         | 0.19 |
| Neck pain                                           | 1         | 0.19 |
| Abdominal pain, diarrhea                            | 1         | 0.19 |
| Muscle and joint pain                               | 1         | 0.19 |

DISCUSSION
In the United Nations (UN) peace mission, Nepalese soldiers gets deployed in the countries allocated by the UN¹. Mefloquine is one of the prophylactic medications recommended by the government of Nepal for soldiers going into different malarious countries in Africa⁶.

Mefloquine has a long elimination half-life of 14 to 41 days, which allows for once-a-week dosing and makes it a popular choice as malaria prophylaxis for travelers to malaria-endemic areas¹. The current recommended prophylactic dose is 250 mg once a week for adults⁸. Since mefloquine was introduced in 1985, the most commonly reported adverse events were gastrointestinal and neuropsychiatric events¹⁶,¹⁸. Psychiatric symptoms after taking mefloquine range from restlessness, aggression, unease, a sense of impending doom, phobias, magical thinking¹², agitation¹⁰,¹¹, memory impairment¹¹,¹², auditory or true visual hallucinations¹¹,¹⁶,²¹,²², frequently involving religious or morbid themes¹¹, insomnia¹⁰,¹⁶,²¹,²², abnormal dreams¹¹,¹²,¹⁵, anxiety¹²,¹³,¹⁵, paranoia¹³,¹⁴, panic attacks¹⁴,¹⁵,¹⁹, personality change¹²,¹³,¹⁵, dizziness¹⁷,¹⁹,²¹,²⁴,²⁵, psychotic behaviour¹⁰,²¹-²⁴,²⁷, suicidal ideation¹⁹,²²,²⁴-²⁷, and suicide¹³,¹⁴,²²,²⁷, delusions¹⁷,¹⁹,²³,²⁷, persecutory mania¹⁶,²¹-²⁴,²⁷, depression²⁵-²⁷ to hallucinations¹⁵,²¹-²⁴,²⁷ and sleep disturbances¹⁹,²¹-²⁴,²⁷. Such symptoms have been reported after only a single 250-mg tablet and may progress in severity with subsequent doses. In some cases, these symptoms have been reported to continue for months or years after mefloquine has been stopped¹⁶.

Neurologic symptoms such as tinnitus¹⁰, dizziness¹⁰,¹³,²⁴ or vertigo¹⁰,¹⁴,²², convulsions¹⁴,¹⁹,²¹,²⁴,²⁵ and loss of balance¹⁵,¹⁹,²⁰ may develop. During prophylactic use, if above mentioned neurologic symptoms occur, the drug should be discontinued, and an alternative medication should be substituted.¹⁵ In the present study, in all four cases, mefloquine was held and only preventive ways like the use of mosquito repellant and net were used. Mefloquine is highly effective in preventing malaria, but articles in the medical and lay press that highlight the neuropsychiatric side effects of mefloquine have caused many travelers to use less-effective alternatives or to avoid chemoprophylaxis altogether⁶. This large study on Nepalese troops deployed in UN peace mission found mefloquine to be relatively safe in an apparently healthy population with only four (7.6/1,000) positive cases with GHQ ≥3. Among neuropsychiatric adverse events associated with mefloquine, insomnia/sleep disturbances and headache were more common (and=3) followed by memory impairment, confusion, dizziness or vertigo and blurred or double vision (n=2).
in the present study. Additionally, most of the previous adverse events related reports on mefloquine were case based studies. So, with proper screening of the individual to rule out any systemic illnesses, mefloquine can be used safely as a prophylactic agent while moving to malarious prone zone judging the benefit over the risk.

This study was based on Nepalese troops posted in Sudan for UN peace mission taking mefloquine as prophylactic regimen so its major limitation could be its generalizability to all populations and ethnicity. So, randomized study including different population is the next step ahead to explore the safety of mefloquine.

CONCLUSION
Mefloquine can be safely used in apparently healthy individuals where malaria is endemic with a high prevalence rate, judging the benefit over the risk of not using it. Individuals should not avoid chemoprophylaxis with mefloquine based on unnecessarily sensationalized media coverage. Though this non-randomized study; based on Nepalese adult population (soldiers) its generalizability may not be applicable in all population groups so further well-designed study including other ethnic population is next to explore the safety of mefloquine.

ACKNOWLEDGMENT
We would like to acknowledge the deployed troops without whom study would not have been possible. Also, we would like to acknowledge the Nepalese army corps for granting permission and needful help to conduct this study.

REFERENCES
1. Nepali Army. नेपाली सेना [Internet]. Kathmandu: Nepal. ©2005-2018. [cited March 27, 2018]. [Website]
2. World Health Organization. International travel and health: situation as on 1 January 2012. Geneva, Switzerland: WHO Press, World Health Organization; 2012 Aug 30. p. 144-67 [FullText]
3. Schlagenhauf P, Adamcova M, Regep L, Schaerer MT, Rhein HG. The position of mefloquine as a 21st century malaria chemoprophylaxis. Malaria journal. 2010 Dec 9;1:357.[DOI]
4. Government of Nepal Ministry of Health and Population, Department of Health Services. ANNUAL REPORT Department of Health Services 2070/71 (2013/2014). Teku, Kathmandu: Government of Nepal Ministry of Health and Population, Department of Health Services; 2015. p. 90. [FullText]
5. Jacquerioz FA, Croft AM. Drugs for preventing malaria in travelers. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD006491.[DOI]
6. Winstanley P. Mefloquine: the benefits outweigh the risks. British journal of clinical pharmacology. 1996 Oct 1;42(4):411-3. [DOI]
7. Goldberg DP, Gater R, Sartorius N, Ustun TB, Piccinelli M, Gureje O et al. The validity of two versions of the GHQ in the WHO study of mental illness in general health care. Psychological medicine. 1997 Jan 27;1(1):191-7.[PubMed]
8. Department of Health Services Ministry of Health and Population Government of Nepal. Nepal Malaria Strategic Plan 2011-2016. Teku, Kathmandu: Department of Health Services, Ministry of Health and Population; 2011 Dec. 86p.[FullText]
9. White NJ, Breman JG. Malaria. In: Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J, editors. Harrison’s Principles of Internal Medicine 19th ed. New Delhi: McGraw-Hill Education; 2015. p. 1368-87.
10. Overbosch D, Schilthuis H, Bienzle U, Behrens RH, Kain KC, Clarke PD et al. Atovaquone-proguanil versus mefloquine for malaria prophylaxis in nonimmune travelers: results from a randomized, double-blind study. Clinical Infectious Diseases. 2001 Oct 1;33(7):1015-21.[DOI]
11. Tuan TM, Browning J, Dell ML. Psychosis with paranoid delusions after a therapeutic dose of mefloquine: a case report. Malaria Journal. 2006 Dec;5(1):74.[DOI]
12. Ritchie EC, Block J, Nevin RL. Psychiatric side effects of mefloquine: applications to forensic psychiatry. Journal of the American Academy of Psychiatry and the Law Online. 2013 Jun 1;41(2):224-35. [PubMed]
13. Teva Pharmaceuticals. Mefloquine Hydrochloride Tablets USP [Internet]. Sellerville, PA, USA: Teva Pharmaceuticals; 2013[Assessed on March 20, 2018] [FullText]
14. Schlagenhauf P. Mefloquine for Malaria Chemoprophylaxis 1992-1998: A Review. J Travel Med 1999; 6: p. 122-33. [FullText]
15. Schlagenhauf P, Steffen R. Neuropsychiatric events and travel: do antimalarials play a role? Journal of travel medicine. 2000 Sep 1;7(5):225-7. [PubMed]
16. Barrett PJ, Emmins PD, Clarke PD, Bradley DJ. Comparison of adverse events associated with use of mefloquine and combination of chloroquine
and proguanil as antimalarial prophylaxis: postal 
and telephone survey of travelers. BMJ. 1996 Aug 
31;313(7056):525-8.[PubMed]

17. Organisation Mondiale de la Sante WHO. Review 
of central nervous system adverse events related 
to the antimalarial drug, mefloquine (1985-1990) 
(WHO/MAL 911063). Geneva: WHO;1991.31 p. 
[FullText]

18. Oueriagli FN, Touhami M, Laffinti A, Abilkacem 
L. Mood disorder after malaria prophylaxis with 
mefloquine (two case reports). L’Encephale. 2011 
Oct;37(5):393-6. [DOI]

19. Borruat FX, Nater B, Robyn L, Genton B. Prolonged 
visual illusions induced by mefloquine (Lariam®): a 
case report. Journal of travel medicine. 2001 May 
1;8(3):148-9. [PMID]

20. Thapa R, Biswas B. Childhood mefloquine-induced 
mania and psychosis: a case report. Journal of child 
neurology. 2009 Aug;24(8):1008-9.

21. Folkerts H, Kuhs H. Psychotic episode caused by 
prevention of malaria with mefloquine. A case 
report. Der Nervenarzt. 1992 May;63(5):300-2. 
[FullText]

22. Meszaros K, Kasper S. Psychopathological 
phenomena in long-term follow-up of acute 
psychosis after preventive mefloquine (Lariam) 
administration. Der Nervenarzt.1996 May;67(5):404- 
6.

23. Tor PC, Lee HY, Tan CH. Mefloquine-induced mania 
in a 22-year-old Chinese man. Singapore medical 
journal. 2006 Jun;47(6):549-50.[PubMed]

24. Fuller SJ, Naraqi S, Gilessi G. Paranoid psychosis 
related to mefloquine antimalarial prophylaxis. 
PAPUA NEW GUINEA MEDICAL JOURNAL. 2002 
Sep;45(3/4):219-21. [PubMed]

25. Office of the Assistant Secretary of defense. Policy 
Memorandum on the Use of Mefloquine in Malaria 
Prophylaxis. [Internet]. Washington: Office of the 
assistant secretary of defense. [Website]

26. Even C, Friedman S, Lanouar K. Bipolar disorder 
after mefloquine treatment. Journal of Psychiatry 
and Neuroscience. 2001 May; 26(3):252. [PubMed]

27. Rønn AM, Rønne Rasmussen J, Gøtzsche PC, 
Bygbjerg IC. Neuropsychiatric manifestations after 
mefloquine therapy for Plasmodium falciparum 
malaria: comparing a retrospective and a 
prospective study. Tropical Medicine & International 
Health. 1998 Feb 1;3(2):83-8. [DOI]